Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk's Smash-Hit Drug Could Become Even More Profitable. Here's Why.
08:15am, Monday, 05'th Jun 2023
Novo Nordisk's heyday with semaglutide is just getting started. There's some evidence to suggest it could be useful in treating addiction.
Novo Nordisk: Dominating In Diabetes And Obesity
01:13am, Monday, 05'th Jun 2023
Novo Nordisk has performed extremely well in the past few years as it continues to dominate in diabetes and obesity. The massive market opportunities alongside the ongoing market share gain should con
Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond.
10:07am, Wednesday, 31'st May 2023
Novo Nordisk's expertise in diabetes care is about to produce another promising medicine. Tandem Diabetes Care is looking to take advantage of the vast insulin-pump opportunity.
This Could Be Novo Nordisk's Next Big Weight-Loss Product
09:45am, Wednesday, 31'st May 2023
The Danish drugmaker recently announced phase 3 trial results for an oral version of Wegovy. The pill version of its popular weight-loss treatment demonstrated similar results to the injection.
Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
10:40am, Tuesday, 30'th May 2023
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Better Dividend Stock: Eli Lilly or Novo Nordisk?
08:45am, Tuesday, 30'th May 2023
Eli Lilly and Novo Nordisk have been two of the hottest dividend-paying pharma stocks of late. While both companies sport well-supported dividends, one company comes with inherently less risk and stro
This Pharma's Sales Are So Hot It's Trying to Curb Demand
05:15am, Tuesday, 30'th May 2023
Novo Nordisk is struggling to keep up with demand for Wegovy. It's experiencing manufacturing problems and delaying new-patient starts.
Novo Nordisk (NVO) Growth Hormone Drug Gets Positive CHMP Opinion
01:35pm, Friday, 26'th May 2023
Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
10:50am, Friday, 26'th May 2023
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The dark side of the weight-loss drug craze: Eating disorders, medication shortages, dangerous knock-offs
10:04am, Friday, 26'th May 2023
A national obsession with a new class of weight-loss drugs is turning dangerous, doctors and researchers say, as many patients are inappropriately prescribed Wegovy, Ozempic and similar medications an
Time to Buy Stock in These Pharmaceutical Giants for EPS Growth
06:48pm, Thursday, 25'th May 2023
The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of hea
3 Biotech Stocks With Blockbuster Potential
09:13pm, Wednesday, 24'th May 2023
When it comes to possibilities of outsized rewards, few sectors can beat out biotech stocks with blockbuster potential. Fundamentally, the underlying sector enjoys a massive footprint.
Novo Nordisk (NVO) Collaborates for Gene-Editing Therapies
04:28pm, Wednesday, 24'th May 2023
Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.
Is Novo Nordisk (NVO) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:58pm, Wednesday, 24'th May 2023
Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.
Pharma industry remains in 'early innings' of new weight loss drug boom, says Scott Gottlieb
03:26pm, Tuesday, 23'rd May 2023
Former FDA Commissioner and Pfizer Board Member Dr. Scott Gottlieb joins 'The Exchange' to discuss the Surgeon General's social media warning, new weight loss drugs coming to market, and the potential
